Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Mon Aug 8, 2022

Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ET...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas Globe Newswire - Thu Aug 4, 2022

Clinical Trial Now Expands to Fifteen U.S. Trial Sites ...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement Globe Newswire - Tue Aug 2, 2022

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies...

SLRX : 0.4848 (-5.05%)
VNRX : 0.6172 (+3.89%)
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 Globe Newswire - Fri Jul 29, 2022

Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals to Participate in BIO International Convention 2022 Globe Newswire - Thu Jun 9, 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference Globe Newswire - Wed May 18, 2022

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results Globe Newswire - Thu May 12, 2022

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration Globe Newswire - Wed May 11, 2022

Salarius planning for SP-3164 IND Application Submission in 2023...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress Globe Newswire - Thu May 5, 2022

Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET...

SLRX : 0.4848 (-5.05%)
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering Globe Newswire - Fri Apr 22, 2022

HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer...

SLRX : 0.4848 (-5.05%)

Barchart Exclusives

2 Top Defense Stocks That Just Won New Army Contracts Barchart - 1 hour ago
Flaring tensions in the Middle East have put the spotlight on defense stocks, and even the cautious analysts at Morgan Stanley name these two picks as their top choices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot